WASHINGTON, October 23 (RIA Novosti) – A US biotech firm has announced that a subsidiary has won a $4.6 million dollar contract in research funding from the Russian Ministry of Trade and Industry, barely a week after announcing an earlier funding agreement with Moscow, a medical news website reported Wednesday.
"Our goal is to advance two of our product candidates into the clinic in the coming year," Michael Fonstein, CEO and president of Cleveland BioLabs subsidiary Panacela said in a statement. "We are honored to partner with the ministry to support a substantial part of our clinical development program."
Under the three-year contract, the Russian ministry has agreed to match Panacela’s funding for clinical and preclinical studies of its cancer vaccine Mobilan, according to News-Medical.net
Ties between Panacela and the Russia government date back to when the firm was founded in 2011 as a joint venture between majority owner Cleveland BioLabs and Russia’s state-run investment firm RUSNANO, News-Medical.net reported.
On Oct. 16 Cleveland BioLabs announced that it had been awarded $4.6 million by the Russian Ministry of Trade and Industry to fund studies into Entolimod, another potential cancer treatment.
